Transactions
6
Insider / Moderna, Inc.
McDonnell Michael R.
Director at Moderna, Inc.
- Company
- Moderna, Inc.
- First filing on record
- February 18, 2026
- Latest trade on record
- July 8, 2026
- SEC filings
- EDGAR ↗
McDonnell Michael R., Director at Moderna, Inc., has disclosed 6 transactions in MRNA, MMSI, BAX since February 18, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed July 10, 2026, 2 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
0
Avg. disclosure lag
2.3d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months McDonnell Michael R. reported 6 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 6 | 32,870 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 6 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | Other A | July 8, 2026 | July 10, 2026 | 2d | 5,733 | — | — | derivative | Form 4 ↗ | |
| MRNA | Other A | July 8, 2026 | July 10, 2026 | 2d | 1,618 | — | — | derivative | Form 4 ↗ | |
| MRNA | Other A | July 8, 2026 | July 10, 2026 | 2d | 7,415 | — | — | derivative | Form 4 ↗ | |
| MMSI | Other A | May 18, 2026 | May 19, 2026 | 1d | 3,457 | — | — | Form 4 ↗ | ||
| BAX | Other A | May 5, 2026 | May 7, 2026 | 2d | 12,836 | — | — | Form 4 ↗ | ||
| BAX | Other A | February 13, 2026 | February 18, 2026 | 5d | 1,811 | — | — | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| July 10, 2026 | Form 4 | 0001682852-26-000139 | 3 | published | EDGAR ↗ |
| May 19, 2026 | Form 4 | 0001121897-26-000002 | 1 | published | EDGAR ↗ |
| May 7, 2026 | Form 4 | 0001628280-26-032141 | 1 | published | EDGAR ↗ |
| February 18, 2026 | Form 4 | 0001628280-26-009023 | 1 | published | EDGAR ↗ |
Other insiders at Moderna, Inc.
- Hoge Stephen President 76 rows
- Mock James M Chief Financial Officer 68 rows
- Klinger Shannon Thyme Chief Legal Officer 64 rows
- Bancel Stephane Chief Executive Officer 15 rows
- Peterson Neil W. CHIEF OPERATING OFFICER 8 rows
- AFEYAN NOUBAR Director 7 rows
- Hussain Abbas Director 7 rows
- SCHLICHTING NANCY M Director 7 rows
- Voigt Michel J. CHIEF HUMAN RESOURCES OFFICER 7 rows
- Wendell Amy McBride Director 7 rows
Everyone on file, with contracts and lobbying under the company's name: Moderna, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 6 | February 18, 2026 | July 10, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.